ClinicalTrials.gg
CompletedNCT04341116Updated May 6, 2023Results posted

Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)

A Phase 2/3 interventional study of TJ003234 and Placebo in Coronavirus Disease 2019 COVID-19, sponsored by I-Mab Biopharma US Limited. Completed at 14 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-06.

Sponsored by I-Mab Biopharma US Limited · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
149
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,859 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.

Enrollment
539th of 1,321
149 · median 91
Started
2020
with 817 others
Phase 2/3
70 of 1,859
1 open now
Registered
90th of 1,859
by date

Among the 1,859 studies in COVID-19 with a site in United States, this one is the 539th largest by enrollment of the 1,321 interventional ones that give a count, is one of 818 that started in 2020, is one of 70 in phase 2/3, and was the 90th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

120 of the 1,859 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,859 studies in COVID-19 with a site in United States, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled, multi-center trial to evaluate the safety and efficacy of TJ003234 administered as an intravenous (IV) infusion in subjects with severe COVID-19 under supportive care, and to assess the effect of TJ003234 on the levels of cytokines.

03

Conditions studied

  • Coronavirus Disease 2019 COVID-19

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: 18 years or older (including 18 years); male or female
  • Laboratory-confirmed SARS-CoV-2 or COVID-19 infection as determined by polymerase chain reaction (PCR) or other commercial or public health assay.
  • Bilateral lung infection confirmed by imaging.
  • Severe disease that meets one of the following conditions: (i) At rest, finger blood oxygen saturation ≤ 93% or PaO2/FiO2 ≤ 300 mmHg; (ii) Requiring non-invasive or invasive mechanical ventilation; OR (iii) Requiring high flow oxygen ≥ 15L/min
  • Hospitalized for no more than 5 calendar days at the time of screening

Exclusion criteria

Exclusion Criteria:

  • Any previous and/or current disease or condition that has not been stable within 3 months prior to enrollment, or acute illness, planned medical/ surgical procedure, or any trauma that occurred within 2 weeks prior to enrollment.
  • (COPD) patients requiring inhaled , long-acting beta-adrenergic agonists, long-acting anticholinergics, or long-term oxygen therapy (Part 1 only).
  • Pulmonary interstitial disease, pulmonary alveolar proteinosis, and pulmonary granulomatosis.
  • Cardiovascular event in the 3 months prior to study drug administration: acute myocardial infarction or unstable angina pectoris, severe arrhythmia (multiple sources of frequent ventricular premature beat, ventricular tachycardia and ventricular fibrillation); Classification (NYHA): Class III-Class IV.
  • Blood system disorders or routine blood analysis test abnormalities: \< 8 g/dL; (ANC) \<1500 × 109/L; \< 50 × 109/L.
  • Dependence on glucocorticoid treatment equivalent to methylprednisolone 2 mg/kg/ day or more or long-term use of anti-rejection or immunomodulatory drugs.
  • Subjects that have been on invasive mechanical ventilation for ≥120 hours at the time of dosing
  • Subjects that require ECMO.
  • Pregnant or breastfeeding females.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
149 participants (actual)

Study arms

  • Experimental
    TJ003234 Medium Dose

    Drug: TJ003234

  • Experimental
    TJ003234 Low Dose

    Part 1 only

    Drug: TJ003234

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Experimental
    TJ003234 High Dose

    Part 2 Phase 3 only

    Drug: TJ003234

Interventions

  • patients receive a single infusion

  • DrugPlacebo

    patients receive a single infusion

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects Alive and Free of Mechanical Ventilation Among Subjects Who Are Free of Mechanical Ventilation at Baseline

    Free of mechanical ventilation was defined as proportion of subjects who scores 1 to 5 in the following 8-category ordinal scale. 8, death; 7, ventilation in addition to extracorporeal membrane oxygen (ECMO), continuous renal replacement therapy (CRRT) or pressors; 6, intubation and mechanical ventilation; 5, non-invasive mechanical ventilation (NIV) or high-flow oxygen; 4, hospitalization with oxygen by mask or nasal prongs; 3. Hospitalization without oxygen supplementation; 2, limitation of activities, discharge from hospital; and 1, no limitation of activities, discharge from hospital.

    Time frame: Day 1 through Day 30

Secondary outcomes

  1. Percentage of Recovery by Day 14

    Sustained recovery in clinical status was defined as patients who have hospitalization without oxygen supplement or discharge from hospital.

    Time frame: Day 1 through Day 14

  2. Percentage of Subjects Recovered on Day 30

    Sustained recovery in clinical status was defined as patients who have hospitalization without oxygen supplement or discharge from hospital.

    Time frame: Day 1 through Day 30

  3. All-cause Mortality Rate by Day 30

    The percentage of subjects who deceased by any cause.

    Time frame: Day 1 through Day 30

  4. Time to Recovery Among Subjects Alive by Day 30

    Time to sustained recovery

    Time frame: Day 1 through Day 30

  5. Length of Hospitalization

    Duration of hospitalization

    Time frame: Day 1 through Day 30

07

Results

Posted May 6, 2023

Participant flow

Participant flow — Overall Study
MilestoneTJ003234 3mg/kg (Part 1)TJ003234 6mg/kg (Part 1)Placebo (Part 1)TJ003234 6mg/kg (Part 2)TJ003234 10mg/kg (Part 2)Placebo (Part 2)
Started88877642
Completed76666534
Not completed1221118

Outcome measures

PrimaryPercentage of Subjects Alive and Free of Mechanical Ventilation Among Subjects Who Are Free of Mechanical Ventilation at Baseline

Free of mechanical ventilation was defined as proportion of subjects who scores 1 to 5 in the following 8-category ordinal scale. 8, death; 7, ventilation in addition to extracorporeal membrane oxygen (ECMO), continuous renal replacement therapy (CRRT) or pressors; 6, intubation and mechanical ventilation; 5, non-invasive mechanical ventilation (NIV) or high-flow oxygen; 4, hospitalization with oxygen by mask or nasal prongs; 3. Hospitalization without oxygen supplementation; 2, limitation of activities, discharge from hospital; and 1, no limitation of activities, discharge from hospital.

Time frame:
Day 1 through Day 30
Reported as:
Count of participants · Participants
Percentage of Subjects Alive and Free of Mechanical Ventilation Among Subjects Who Are Free of Mechanical Ventilation at Baseline
ParticipantsTJ003234 6mg/kg (Part 1)Placebo (Part 1)TJ003234 6mg/kg (Part 2)TJ0032034 10mg/kg (Part 2)Placebo (Part 2)
Percentage of Subjects Alive and Free of Mechanical Ventilation Among Subjects Who Are Free of Mechanical Ventilation at Baseline——56527
Statistical analysis
  • TJ003234 6mg/kg (Part 2) vs TJ0032034 10mg/kg (Part 2) · Fisher Exact · p = .28 · Median difference (final values): 9 · 95% CI -6.5 to 27
SecondaryPercentage of Recovery by Day 14

Sustained recovery in clinical status was defined as patients who have hospitalization without oxygen supplement or discharge from hospital.

Time frame:
Day 1 through Day 14
Reported as:
Count of participants · Participants
Percentage of Recovery by Day 14
ParticipantsTJ003234 6mg/kg (Part 1)Placebo (Part 1)TJ003234 6mg/kg (Part 2)TJ003234 10mg/kg (Part 2)Placebo (Part 2)
Percentage of Recovery by Day 14——47520
SecondaryPercentage of Subjects Recovered on Day 30

Sustained recovery in clinical status was defined as patients who have hospitalization without oxygen supplement or discharge from hospital.

Time frame:
Day 1 through Day 30
Reported as:
Count of participants · Participants
Percentage of Subjects Recovered on Day 30
ParticipantsTJ003234 6mg/kg (Part 1)Placebo (Part 1)TJ003234 6mg/kg (Part 2)TJ003234 10mg/kg (Part 2)Placebo (Part 2)
Percentage of Subjects Recovered on Day 30——56527
SecondaryAll-cause Mortality Rate by Day 30

The percentage of subjects who deceased by any cause.

Time frame:
Day 1 through Day 30
Reported as:
Count of participants · Participants
All-cause Mortality Rate by Day 30
ParticipantsTJ003234 6mg/kg (Part 1)Placebo (Part 1)TJ003234 6mg/kg (Part 2)TJ003204 10mg/kg (Part 2)Placebo (Part 2)
All-cause Mortality Rate by Day 30——719
SecondaryTime to Recovery Among Subjects Alive by Day 30

Time to sustained recovery

Time frame:
Day 1 through Day 30
Reported as:
Median · days
Time to Recovery Among Subjects Alive by Day 30
daysTJ003234 6mg/kg (Part 1)Placebo (Part 1)TJ003234 6mg/kg (Part 2)TJ004309 10mg/kg (Part 2)Placebo (Part 2)
Time to Recovery Among Subjects Alive by Day 30——8 (5 to 18)6.5 (4.0 to 10.0)10 (4 to 22)
SecondaryLength of Hospitalization

Duration of hospitalization

Time frame:
Day 1 through Day 30
Reported as:
Median · days
Length of Hospitalization
daysTJ003234 6mg/kg (Part 1)Placebo (Part 1)TJ003234 6mg/kg (Part 2)TJ003234 10mg/kg (Part 2)Placebo (Part 2)
Length of Hospitalization——10 (8 to 13)9.5 (1 to 12)11 (7 to 18)

Adverse events

Collected over All adverse events will be collected from the day of informed consent to Day 30.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TJ003234 3 mg/kg (Part 1)1/8 (12.5%)2/8 (25%)0/8 (0%)
TJ003234 6mg/kg (Part 1)1/8 (12.5%)4/8 (50%)0/8 (0%)
Placebo (Part 1)2/8 (25%)2/8 (25%)0/8 (0%)
TJ003234 6 mg/kg (Part 2)11/77 (14.3%)22/77 (28.6%)0/77 (0%)
TJ003234 10mg/kg (Part 2)1/6 (16.7%)1/6 (16.7%)0/6 (0%)
Placebo (Part 2)10/42 (23.8%)16/42 (38.1%)0/42 (0%)
Most frequent serious events
Showing 10 of 42
Most frequent serious events
EventTJ003234 3 mg/kg (Part 1)TJ003234 6mg/kg (Part 1)Placebo (Part 1)TJ003234 6 mg/kg (Part 2)TJ003234 10mg/kg (Part 2)Placebo (Part 2)
(WORSENING) HYPOXIC RESPIRATORY FAILURERespiratory, thoracic and mediastinal disorders0/80/80/813/770/65/42
(Worsening) PNEUMONIA (due to COVID-19)Infections and infestations0/80/80/83/771/61/42
Cardiac ArrestCardiac disorders0/81/80/82/770/60/42
SEPTIC SHOCKInfections and infestations0/81/80/86/770/64/42
ACUTE KIDNEY INJURYRenal and urinary disorders1/80/80/82/770/63/42
COVID-19Infections and infestations1/81/81/80/770/60/42
PNEUMONIA BACTERIALInfections and infestations0/80/81/80/770/60/42
Staphylococcal bacteraemiaInfections and infestations0/80/81/80/770/60/42
MyopathyMusculoskeletal and connective tissue disorders0/81/80/80/770/60/42
Pneumonia aspirationRespiratory, thoracic and mediastinal disorders0/80/81/80/770/60/42

Baseline characteristics

Age, Continuous
Age, Continuous(years)TJ003234 3mg/kg (Part 1)TJ003234 6mg/kg (Part 1)Placebo (Part 1)TJ003234 6mg/kg (Part 2)TJ003234 10mg/kg (Part 2)Placebo (Part 2)Total
Mean51.9 (36 to 80)58.4 (39 to 75)58 (19 to 80)55.6 (24 to 84)57.2 (31 to 75)56.4 (37 to 77)56 (19 to 84)
Sex: Female, Male
Sex: Female, Male(Participants)TJ003234 3mg/kg (Part 1)TJ003234 6mg/kg (Part 1)Placebo (Part 1)TJ003234 6mg/kg (Part 2)TJ003234 10mg/kg (Part 2)Placebo (Part 2)Total
Female4344942488
Male4542821861
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)TJ003234 3mg/kg (Part 1)TJ003234 6mg/kg (Part 1)Placebo (Part 1)TJ003234 6mg/kg (Part 2)TJ003234 10mg/kg (Part 2)Placebo (Part 2)Total
Hispanic or Latino0113321653
Not Hispanic or Latino8774442696
Unknown or Not Reported0000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)TJ003234 3mg/kg (Part 1)TJ003234 6mg/kg (Part 1)Placebo (Part 1)TJ003234 6mg/kg (Part 2)TJ003234 10mg/kg (Part 2)Placebo (Part 2)Total
American Indian or Alaska Native0002013
Asian0002024
Native Hawaiian or Other Pacific Islander0000011
Black or African American4332331046
White4553932177
More than one race000110617
Unknown or Not Reported0000011
Region of Enrollment
Region of Enrollment(participants)TJ003234 3mg/kg (Part 1)TJ003234 6mg/kg (Part 1)Placebo (Part 1)TJ003234 6mg/kg (Part 2)TJ003234 10mg/kg (Part 2)Placebo (Part 2)Total
United States88877642149
Height
Height(cm)TJ003234 3mg/kg (Part 1)TJ003234 6mg/kg (Part 1)Placebo (Part 1)TJ003234 6mg/kg (Part 2)TJ003234 10mg/kg (Part 2)Placebo (Part 2)Total
Mean168.8 (144.8 to 190.5)166.8 (147.3 to 185.4)173.3 (160.0 to 190.5)167.1 (72.0 to 190.5)171.0 (160.0 to 182.9)168.3 (149.9 to 188.0)168.65 (72.0 to 190.5)
Weight
Weight(kg)TJ003234 3mg/kg (Part 1)TJ003234 6mg/kg (Part 1)Placebo (Part 1)TJ003234 6mg/kg (Part 2)TJ003234 10mg/kg (Part 2)Placebo (Part 2)Total
Mean101.4 (43.9 to 161.0)88.0 (74.0 to 138.3)108.9 (53.0 to 145.0)97.2 (43.9 to 161.0)98.1 (74.0 to 138.3)97.1 (53.0 to 145.0)98.3 (43.9 to 161.0)
Mechanical Ventilation
Mechanical Ventilation(Participants)TJ003234 3mg/kg (Part 1)TJ003234 6mg/kg (Part 1)Placebo (Part 1)TJ003234 6mg/kg (Part 2)TJ003234 10mg/kg (Part 2)Placebo (Part 2)Total
Yes333100625
No31267636115
Unknown2430009
08

Study locations

14 sites
  • University of Arkansas
    Little Rock, Arkansas 72205, United States
  • Olive View-UCLA Medical Center
    Sylmar, California 91342, United States
  • Georgetown University Hospital
    Washington, District of Columbia 20007, United States
  • The GW Medical Faculty Associates
    Washington, District of Columbia 20037, United States
  • University of Miami
    Miami, Florida 33146, United States
  • OSF Healthcare Saint Francis Medical Center
    Peoria, Illinois 61637, United States
  • Indiana University Health
    Indianapolis, Indiana 46202, United States
  • Medpharmics, LLC
    Metairie, Louisiana 70006, United States
  • Ochsner Medical Center
    New Orleans, Louisiana 70121, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • University of Mississippi Medical Center
    Jackson, Mississippi 39216, United States
  • University Medical Center of Southern Nevada
    Las Vegas, Nevada 89102, United States
  • UNM Hospitals
    Albuquerque, New Mexico 87106, United States
  • Houston Methodist Hospital
    Houston, Texas 77030, United States
09

References and documents

Publications

  • Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, Neidhardt M, Piechotta V, Salomon S, Valk SJ, Monsef I, Schmaderer C, Wood EM, So-Osman C, Roberts DJ, McQuilten Z, Estcourt LJ, Skoetz N. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2. PubMed 34473343 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2020 to primary completion in Feb 2022, 21 months.

Results were first posted in May 2023, 1 year 2 months after primary completion.

Of 73 industry-sponsored phase 2/3 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's 21 months is above that.

Counting every sponsor, half of 168 studies reached it within 11 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2020
First posted
Apr 10, 2020
StartActual
Apr 11, 2020
Primary completionActual
Feb 7, 2022
CompletionActual
Feb 7, 2022
Results first posted
May 6, 2023
Last update
May 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04341116
Lead sponsor
I-Mab Biopharma US Limited
Responsible party
Sponsor
First posted
Apr 10, 2020
Start date
Apr 11, 2020
Primary completion
Feb 7, 2022
Completion
Feb 7, 2022
Results posted
May 6, 2023
Last update
May 6, 2023

Study contacts

Claire Xu, MD, PhD
study director · I-Mab Biopharma US Limited

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Plonmarlimab

Start the discussion